SINGAPORE / HONG KONG, 15 February 2022 – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company focused on improving and saving lives with RNA-powered cancer early detection tests, announced today the set-up of its Hong Kong office and the appointment of Mr. Martin LAW as Managing Director in Hong Kong, who will report to MiRXES’s Co-founder and CEO, Dr. Lihan ZHOU. Mr. Law will lead the establishment and operations of MiRXES Hong Kong Limited, to explore partnerships in providing accurate, affordable and accessible cancer early detection to the Hong Kong and Greater Bay Area communities
MiRXES, a leading cancer early detection company with a network of six offices in Asia and North America, is accelerating its multi-cancer pipeline development and intensifying commercial expansion following a successful US$87 million Series C funding in 2021. Backed by its unique best-in-class miRNA PCR technology, strong clinical pipeline, and state-of-the-art manufacturing and laboratory infrastructure, MiRXES is well-positioned to deliver holistic cancer early detection solutions complemented by a harmonious pharma, clinical, and payer partnership model.
Mr. Law’s initial focus will be on hiring of key talents for MiRXES Hong Kong Limited as well as developing marketing and communications plans to increase brand awareness and product recognition, to support its business expansion in Hong Kong and the Greater Bay Area. MiRXES Hong Kong will explore strategic partnerships with regional academic and clinical institutions as well as payers to develop tailored cancer early detection solutions.
“Hong Kong is an excellent starting base for MiRXES’s foray into the Greater Bay Area given its accessibility and connection to the surrounding countries. Both its public and private sectors have shown great support to the biotechnology industry, and Hong Kong’s capital market is mature and active, making it highly attractive for MiRXES to enter,” said Dr. Zhou. “We are delighted to have Martin join the talented MiRXES family as a senior leader, and I am confident that his diverse experience will be a great asset to MiRXES’s regional expansion, especially in Hong Kong.”
Mr. Law brings with him 30 years of experience in consulting, corporate development, and corporate finance, in industries such as banking, insurance, and medical and healthcare services. He was previously the Chief Financial Officer of Hong Kong Exchanges and Clearing Limited (HKEX) listed EC Healthcare Group, Hong Kong’s largest non-hospital medical service provider operating 90 clinics and centers providing multi-disciplinary medical and healthcare services, focusing on preventive and precision medicine. Mr. Law is also the Independent Non-Executive Director (INED) of Liaoning Port Co. Ltd. and Shukun Technology Co. Ltd. respectively.
Mr. Law said, “Hong Kong has an increased awareness of preventive and precision healthcare over the last 10 years, activated and supported by promotions from both government and private sectors. This is an opportune time to enter Hong Kong and enable MiRXES’s proprietary RNA technology used in its disease early detection solutions to benefit the people in both Hong Kong and the Greater Bay Area. I am honoured to be part of this exciting journey to save and improve lives, and to assist MiRXES in bringing the region’s preventive healthcare ecosystem to the next level.”
Mr. Law holds an MBA from Hong Kong Baptist University. He is a Chartered Management Accountant (ACMA), Chartered Global Management Accountant (CGMA), Certified Information Systems Auditor (CISA), as well as an Associate of the Chartered Institute of Arbitrator (ACIArb). Mr. Law is also a Fellow of the Hong Kong Institute of Directors (FHKIoD).
Founded in 2014 as a spin-off from Singapore’s Agency for Science, Technology, and Research (A*STAR) with strong support from the National University of Singapore (NUS), MiRXES is a leading developer of RNA-powered tests for disease early detection, with strong pipelines in multiple cancer types, as well as in cardiovascular, metabolic and infectious diseases. MiRXES is headquartered in Singapore, with operations in China, Japan and the United States, as well as commercial activities in over 45 countries globally. In 2019, MiRXES launched GASTROClear, the world’s first microRNA blood test for early detection of gastric cancer. The MiRXES’s multi-cancer early detection pipeline includes screening tests for lung, colorectal, liver, and breast cancer. In response to the COVID-19 pandemic in 2020, MiRXES worked closely with A*STAR, Diagnostics Development Hub (DxD) and Tan Tock Seng Hospital (TTSH) to mass produce Fortitude Kit, Singapore’s first authorized COVID-19 RT-PCR test. Since February 2020, more than 8 million Fortitude Kits have been deployed globally.
For more information, visit www.mirxes.com
Follow us on LinkedIn, Facebook and Instagram.